A recent European licensing deal between Orphan Europe and Erytech Pharma SA on a novel formulation of asparaginase, called Graspa, is further evidence of the commercial revitalization of a long-established treatment in hematologic cancer.
Eporgen Venture SpA, an Italian early stage venture capital fund with a diversified investor base, has logged the first major transaction of its portfolio, the licensing of a therapeutic cancer vaccine program, GX301, from Genovax srl to Mediolanum Farmaceutici SpA.
Lanthio Pharma BV found an influential backer for its peptide technology in the shape of antibody developer MorphoSys AG, which has participated in its €4.8 million (US$6.2 million) Series A round and which will help it to develop and commercialize its LanthioPep platform.
Continuing Europe's recent push in cell therapy development, TxCell SA raised €12.4 million (US$16. 1 million) in a Series C round to fund a Phase IIb study of its OvaSave autologous cell therapy in patients with refractory Crohn's disease.
Lanthio Pharma BV found an influential backer for its peptide technology in the shape of antibody developer MorphoSys AG, which has participated in its €4.8 million (US$6.2 million) Series A round and which will help it to develop and commercialize its LanthioPep platform.
STOCKHOLM & UPPSALA, Sweden – The scaling up of university-based drug discovery research in the Stockholm-Uppsala region, just as AstraZeneca plc is exiting from that same activity, neatly encapsulates an industry trend that has created both headaches and opportunities for Europe's leading bioscience research centers.
Continuing Europe's recent push in cell therapy development, TxCell SA raised €12.4 million (US$16.1 million) in a Series C round to fund a Phase IIb study of its OvaSave autologous cell therapy in patients with refractory Crohn's disease.
Health spending across Europe fell in 2010 for the first time since 1975 as the economic crisis started to bite and governments started to cut back on expenditures, according to a newly published report on health care spending in Europe.
Zealand Pharmaceuticals A/S is set to join what is still an all too select club of European biotechnology firms with a product approval under their belts.
Health spending across Europe fell in 2010 for the first time since 1975 as the economic crisis started to bite and governments started to cut back on expenditures, according to a newly published report on health care spending in Europe.
